Physician profile
C Mark Rose
NPI 1265408215
$12,930.86
in general payments reported to CMS, 2019-2025
60 companies · $2,426 in 2025
The $2,426 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,873 · 2020: $1,168 · 2021: $1,491 · 2022: $1,724 · 2023: $1,990 · 2024: $2,261 · 2025: $2,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,596 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,595.99 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,993.06 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,195.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $969.63 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $878.66 | 2019-2025 | |
| Abbott Laboratories | $850.23 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $825.43 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $487.37 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $434.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sunovion Pharmaceuticals INC. | $370.88 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.80 | 2019-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $327.42 | 2020-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $321.42 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Amgen INC. | $303.83 | 2019-2025 | Repatha, Otezla, Otezla |
| Sumitomo Pharma America, INC. | $302.19 | 2023-2025 | Gemtesa |
| Mylan Specialty L.P. | $287.91 | 2019-2024 | Yupelri |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw C Mark Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.